CRVS Quote, Financials, Valuation and Earnings

Cara Therapeutics has a net margin of -- compared to Corvus Pharmaceuticals's net margin of -488.11%. Corvus Pharmaceuticals's return on equity of -- beat Cara Therapeutics's return on equity of -258.41%.

Corvus Pharmaceuticals has a consensus price target of $15.75, signalling upside risk potential of 221.43%. On the other hand Cara Therapeutics has an analysts' consensus of $1.01 which suggests that it could grow by 117.86%. Given that Corvus Pharmaceuticals has higher upside potential than Cara Therapeutics, analysts believe Corvus Pharmaceuticals is more attractive than Cara Therapeutics.

Corvus Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.936% more volatile than S&P 500. In comparison Cara Therapeutics has a beta of 0.641, suggesting its less volatile than the S&P 500 by 35.853%.

Corvus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corvus Pharmaceuticals pays -- of its earnings as a dividend. Cara Therapeutics pays out -- of its earnings as a dividend.

Corvus Pharmaceuticals quarterly revenues are --, which are smaller than Cara Therapeutics quarterly revenues of $2.6M. Corvus Pharmaceuticals's net income of -$40.2M is lower than Cara Therapeutics's net income of -$12.5M. Notably, Corvus Pharmaceuticals's price-to-earnings ratio is -- while Cara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corvus Pharmaceuticals is -- versus 2.92x for Cara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Corvus Pharmaceuticals's net margin of --. Corvus Pharmaceuticals's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Corvus Pharmaceuticals has a consensus price target of $15.75, signalling upside risk potential of 221.43%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than Corvus Pharmaceuticals, analysts believe Perspective Therapeutics is more attractive than Corvus Pharmaceuticals.

Corvus Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.936% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Corvus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corvus Pharmaceuticals pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Corvus Pharmaceuticals quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Corvus Pharmaceuticals's net income of -$40.2M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Corvus Pharmaceuticals's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corvus Pharmaceuticals is -- versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Clearside Biomedical has a net margin of -- compared to Corvus Pharmaceuticals's net margin of -740.66%. Corvus Pharmaceuticals's return on equity of -- beat Clearside Biomedical's return on equity of --.

Corvus Pharmaceuticals has a consensus price target of $15.75, signalling upside risk potential of 221.43%. On the other hand Clearside Biomedical has an analysts' consensus of -- which suggests that it could grow by 545.86%. Given that Clearside Biomedical has higher upside potential than Corvus Pharmaceuticals, analysts believe Clearside Biomedical is more attractive than Corvus Pharmaceuticals.

Corvus Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.936% more volatile than S&P 500. In comparison Clearside Biomedical has a beta of 2.292, suggesting its more volatile than the S&P 500 by 129.225%.

Corvus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clearside Biomedical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corvus Pharmaceuticals pays -- of its earnings as a dividend. Clearside Biomedical pays out -- of its earnings as a dividend.

Corvus Pharmaceuticals quarterly revenues are --, which are smaller than Clearside Biomedical quarterly revenues of $1M. Corvus Pharmaceuticals's net income of -$40.2M is lower than Clearside Biomedical's net income of -$7.7M. Notably, Corvus Pharmaceuticals's price-to-earnings ratio is -- while Clearside Biomedical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corvus Pharmaceuticals is -- versus 8.49x for Clearside Biomedical. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Corvus Pharmaceuticals's net margin of 7.2%. Corvus Pharmaceuticals's return on equity of -- beat Sarepta Therapeutics's return on equity of 12.48%.

Corvus Pharmaceuticals has a consensus price target of $15.75, signalling upside risk potential of 221.43%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 51.85%. Given that Corvus Pharmaceuticals has higher upside potential than Sarepta Therapeutics, analysts believe Corvus Pharmaceuticals is more attractive than Sarepta Therapeutics.

Corvus Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.936% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

Corvus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corvus Pharmaceuticals pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Corvus Pharmaceuticals quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Corvus Pharmaceuticals's net income of -$40.2M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Corvus Pharmaceuticals's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 79.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corvus Pharmaceuticals is -- versus 7.48x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.